Does the prostate volume always effect cancer detection rate in prostate biopsy? Additional role of prostate-specific antigen levels: A retrospective analysis of 2079 patients

2019 ◽  
Vol 45 (2) ◽  
pp. 103-107 ◽  
Author(s):  
Engin Kandirali ◽  
◽  
Mustafa Zafer Temiz ◽  
Aykut Colakerol ◽  
Emrah Yuruk ◽  
...  
Keyword(s):  
Retrospective Analysis ◽  
Prostate Specific Antigen ◽  
Cancer Detection ◽  
Prostate Biopsy ◽  
Detection Rate ◽  
Prostate Volume ◽  
Specific Antigen ◽  
Cancer Detection Rate ◽  
Additional Role

scholarly journals Prostate cancer detection rate in patients with fluctuating prostate-specific antigen levels on the repeat prostate biopsy

2014 ◽  
Vol 2 (1) ◽  
pp. 26-30 ◽  
Author(s):  
Yong Hyun Park ◽  
Jung Keun Lee ◽  
Jin-Woo Jung ◽  
Byung Ki Lee ◽  
Sangchul Lee ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Cancer Detection ◽  
Prostate Biopsy ◽  
Detection Rate ◽  
Specific Antigen ◽  
Cancer Detection Rate ◽  
Prostate Cancer Detection

scholarly journals The sufficiency of 6 core sextant prostate biopsy in patients with prostate specific antigen (PSA) values over 20 ng/mL

2018 ◽  
Vol 90 (2) ◽  
pp. 104 ◽  
Author(s):  
Cem Yücel ◽  
Salih Budak ◽  
Erdem Kısa ◽  
Orcun Celik ◽  
Zafer Kozacıoglu
Keyword(s):  
Cancer Detection ◽  
Prostate Biopsy ◽  
Core Biopsy ◽  
Detection Rate ◽  
Prostate Volume ◽  
Specific Antigen ◽  
Cancer Detection Rate ◽  
Benign Pathology ◽  
Total Psa ◽  
Group 1

Objective: In this study, we aimed to investigate sufficiency of 6 core prostate biopsy in patients with PSA levels elevated above 20 ng/mL. Materials and methods: The medical record of the patients who received prostate biopsy at our institution between August 2011 to August 2016 who had serum total PSA values above 20 ng/mL, were reviewed retrospectively. In this study, we included 40 patients who received 6 core prostate biopsy and 40 patients who received 12 core prostate biopsy. A total number of 80 patients were enrolled in this study. Patients were divided into two groups, a 6 core biopsy group and a 12 core biopsy group. These groups are compared according to age, total PSA, prostate volume and final pathological diagnosis.Results: Based on final pathological diagnosis, 2 patients (5%) had benign pathology and 38 patients (95%) had PCa in both group 1 and 2. The cancer detection rate in both groups was 95%. Although there were higher values of mean age, mean total PSA, and mean prostate volume in group 1, there was no statistically significantly difference at this variables in both groups. Conclusion: Although taking 6 core biopsies is not recently recommended, we proved that 6 core biopsy is adequate for patients with PSA values above 20 ng/mL.

scholarly journals The 20-core prostate biopsy as an initial strategy: impact on the detection of prostatic cancer

2013 ◽  
Vol 4 (2) ◽  
pp. 100 ◽  
Author(s):  
Mohamed Amine Jradi ◽  
Mohamed Dridi ◽  
Mourad Teyeb ◽  
Mokhtar Ould Sidi Mohamed ◽  
Ramzi Khiary ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Detection ◽  
Prostate Biopsy ◽  
Detection Rate ◽  
Prostate Volume ◽  
Cancer Detection Rate ◽  
Dépistage Du Cancer ◽  
Biopsy Protocol ◽  
Group 2 ◽  
Group 1

Introduction: To increase the detection rate of prostate cancer inrecent years, we examined the increase in the number of corestaken at initial prostate biopsy. We hypothesized that an increasingnumber of cores may undermine the accuracy of models predictingthe presence of prostate cancer at initial biopsy in patientssubmitted to 20-core initial biopsy.Methods: A total of 232 consecutive patients with prostatespecificantigen (PSA) between 4 and 20 ng/mL and/or abnormaldigital rectal examination (DRE) underwent 12-core prostate biopsyprotocol (group 1) or 20-core prostate biopsy protocol (group 2).The patients were divided into subgroups according to the resultsof their serum PSA and prostate volume. We evaluated the cancerdetection rate overall and in each subgroup. Clinical datawere analyzed using chi-square analysis and the unpaired t-testor 1-way ANOVA with significance considered at 0.05.Results: The 2 groups of patients were not significantly different withregard to parameters (age, abnormal DRE and serum PSA), althoughmedian prostate volume in group 1 (57.76 ± 26.94 cc) were slightergreater than in group 2. Cancer detection rate for patients submittedto 20 prostate biopsy was higher than patients submitted to 12prostate biopsy (35.2% vs. 25%, p = 0.095). Breakdown to PSAlevel showed a benefit to 20 prostate biopsy for PSA <6 ng/mL (37.1%vs. 12.9%, p = 0.005). Stratifying results by prostate volume, wefound that the improvement of cancer detection rate with 20 prostatebiopsy was significant in patients with a prostate volume greaterthan 60 cc (55% in 20 prostate biopsy vs. 11.3% p < 0.05). Morbidityrates were identical in groups 1 and 2 with no statistically significantdifference. There appeared to be no greater risk of infectionand bleeding with 20 prostate biopsy protocol.Conclusion: The 20-core biopsy protocol was more efficient thanthe 12-core biopsy protocol, especially in patients with prostatespecific antigen <6 ng/mL and prostate volume greater than 60 cc.Introduction : Pour augmenter le taux de détection du cancer de laprostate dans un avenir rapproché, nous avons examiné l’incidenced’une hausse du nombre de carottes prélevées lors de la biopsieprostatique initiale. Notre hypothèse était qu’en raison du nombreaccru de prélèvements, la biopsie à 20 carottes pouvait réduirel’exactitude des modèles de dépistage du cancer de la prostate à labiopsie initiale.Méthodologie : Au total, 232 patients consécutifs avec des tauxd’antigène prostatique spécifique (APS) situés entre 4 et 20 ng/mLet/ou des anomalies au toucher rectal ont subi une biopsie prostatiqueà 12 (groupe 1) ou à 20 carottes (groupe 2). Les patients ontété répartis en sous-groupes en fonction de leurs taux sériques d’APSet de leur volume prostatique. Nous avons évalué le taux de dépistagedu cancer de façon globale et par sous-groupes. Les données cli -niques ont été analysées par la méthode du chi carré et du test tpour échantillons non appariés ou par analyse unilatérale de lavariance (ANOVA), avec un seuil de signification de 0,05.Résultats : On n’a noté aucune différence significative entre lesdeux groupes quant aux paramètres (âge, anomalie au toucher rectalet taux sériques d’APS), malgré que le volume prostatique médianait été légèrement supérieur dans le groupe 1 (57,76 ± 26,94 mL)par rapport au groupe 2. Le taux de dépistage du cancer avec labiopsie prostatique à 20 carottes était plus élevé que le taux obtenuavec la biopsie à 12 carottes (35,2 % vs 25 %, p = 0,095). La répartitiondes patients en fonction des taux d’APS a fait ressortir unavantage pour la biopsie à 20 carottes lorsque les taux d’APS étaientinférieurs à 6 ng/mL (37,1 % vs 12,9 %, p = 0,005). La stratificationdes données selon le volume de la prostate a montré que lahausse des taux de dépistage du cancer associée à la biopsie prostatiqueà 20 carottes était significative lorsque le volume prostatiquedépassait 60 mL (55 % pour la biopsie à 20 carottes vs 11,3 %,p < 0,05). Les taux de morbidité étaient semblables dans les deuxgroupes, la différence n’étant pas significative sur le plan statistique.La biopsie prostatique à 20 carottes ne semblait pas associéeà un risque plus élevé d’infection et d’hémorragie.Conclusion : La biopsie à 20 carottes était plus efficace que la biopsieà 12 carottes, surtout chez les patients dont le taux d’APS était

Sign in / Sign up

Export Citation Format

Share Document